Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 8/20 | 0.71 |
| ▸ | BID | P55957 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.39 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157327 | 0.97 | GPR35 (0.75) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL12487323 | 0.97 | GPR35 (0.75) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL9948994 | 0.91 | GPR35 (0.66) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL2180174 | 0.90 | GPR35 (0.65) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL1030731 | 0.90 | GPR35 (0.72) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL13961905 | 0.89 | GPR35 (0.59) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL13961892 | 0.89 | GPR35 (0.59) | GPR35BIDMCL1PPARABCL2L1 | |
| SCHEMBL404495 | 0.83 | GPR35 (1.00) | GPR35 | |
| SCHEMBL2278156 | 0.83 | GPR35 (1.00) | GPR35 | |
| SCHEMBL400817 | 0.83 | GPR35 (1.00) | GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| WO-2011081971-A2 | EGFR/VEGFR DUAL MODULATORS AND METHODS OF USING | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | GPR35 1127/4885BID 532/4885MCL1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.